Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 - Episode 8

Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

March 12, 2025

Shubham Pant, MD, Haley Ellis, MD , Amit Mahipal, MD, Darshil Shah, MD, MPH

Panelists discuss how the DESTINY-PanTumor 02 trial demonstrated significant efficacy of trastuzumab deruxtecan in HER2-amplified biliary tract cancer (BTC), with promising response rates and durability that support its use as a treatment option for these patients.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Guiding Patients Through Advanced BTC Prognosis and Expectations

EP. 2: The Importance of Early Biomarker Testing in Managing Advanced BTC

EP. 3: Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP. 4: Expert Insights: Challenges With ctDNA Testing in BTC

EP. 5: Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP. 6: Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

EP. 7: Understanding HER2 Testing in BTC: Detection and Clinical Approaches

Now Viewing

EP. 8: Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

EP. 9: New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

EP. 10: Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

EP. 11: Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

EP. 12: Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

EP. 13: Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Video content above is prompted by the following:

We have several currently available therapies for those with HER2-amplified and HER2-positive tumors. What are your main takeaways from the DESTINY-PanTumor 02 trial with trastuzumab deruxtecan?